F

FREILONE R.

Last name: FREILONE R.

2021 (v1)

Publication

Metadata-only

Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice

Clavio M. Crisa E. Miglino M.

Azacitidine (AZA) is the standard treatment for myelodysplastic syndromes (MDS); however, many patients prematurely stop therapy and have a dismal outcome.

Uploaded on: February 14, 2024